Lexatumumab (HGS 1018) is a TRAIL-R2 Agonist Antibody
TRAIL-R2 (TNF-related apoptosis-inducing ligand receptor 2), also known as death receptor 5 (DR5), is a cell surface receptor that binds TRAIL, a cytokine that causes apoptosis. Additionally, TRAIL-R2 contains two extracellular cysteine-rich repeats and a cytoplasmic death domain. The receptor engages a caspase-dependent apoptotic pathway. It mediates apoptosis via...
Benufutamab (GEN1029) is a DR5-Specific Agonistic Antibody for Solid Tumor Research
Death receptor 5 (DR5), also known as TRAIL receptor 2 (TRAILR2) and TNFR superfamily member 10B (TNFRSF10B), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Triggering of these receptors via TRAIL or agonistic antibodies selectively induced apoptosis in malignant cells derived from...
Tigatuzumab (CS-1008) is a Humanized Death Receptor 5 (DR5) IgG1 mAb
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the TNF superfamily of cytokines, is a type 2 membrane protein expressed in the majority of normal tissues. TRAIL can undergo protease cleavage, resulting in a soluble form able to bind to TRAIL death receptors (DRs). Moreover, TRAIL induces apoptosis...